

ALLIGATOR BIOSCIENCE PUBLISHES FINANCIAL CALENDAR FOR 2025

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025:

Extraordinary General Meeting	13 January 2025
Deadline for Alligator Bioscience's shareholders to submit resolutions to be considered by the Annual General Meeting	31 January 2025
Year-end report 2024	22 January 2025
Annual report 2024	March 2025
Interim report Q1 2025	24 April 2025
Annual General Meeting	7 May 2025
Interim report H1 2025	10 July 2025
Interim report Q3 2025	23 October 2025
Year-end report 2025	12 February 2026

For further information, please contact:

Søren Bregenholt, CEO

E-mail: soren.bregenholt@alligatorbioscience.com

Phone: +46 (0) 46 540 82 00

Johan Giléus, CFO

E-mail: johan.gileus@alligatorbioscience.com

Phone: +46 (0) 46 540 82 00

The information was submitted for publication, through the agency of the contact person set out above, at 08:45 a.m. CET on December 4, 2024.

PRESS RELEASE 04 December 2024 08:45:00 CET



About Alligator Bioscience

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. Its portfolio includes lead drug candidate mitazalimab, for which the company reported unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in Phase 2 testing and is in preparation for Phase 3 development. The follow-on bispecific antibody ATOR-4066 is in preclinical testing. Alligator has a proprietary technology platform, comprised of two antibody libraries, ALLIGATOR-GOLD® and ALLIGATOR-FAB™, the powerful protein optimization strategy FIND® and the bispecific antibody format RUBY™, which drives rapid design and development of innovative drugs.

Alligator is listed on Nasdag Stockholm (ATORX) and headquartered in Lund, Sweden.

For more information, please visit **alligatorbioscience.com**.

Attachments

Alligator Bioscience publishes financial calendar for 2025